Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations; Draft Guidance for Industry; Availability

1 organizations filed 1 public comment on Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 2563d ago.

Commenters (1)

• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%